Menczer J, Ben-Baruch G, Modan M, Brenner H
Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Gynecol Obstet Invest. 1989;27(2):102-4. doi: 10.1159/000293630.
Sixteen ovarian carcinoma patients who received 12 courses and 21 patients who received 8 courses of cisplatin-based combination chemotherapy were compared. The two groups showed similar rates of second-look laparotomy (10/16 vs. 14/21) and similar rates of negative second-look laparotomies (6/10 vs. 9/14). The advantages of earlier reexploration are possibly lower toxicity and earlier recognition of patients with tumors resistant to the initial chemotherapy.
对16例接受了12个疗程基于顺铂联合化疗的卵巢癌患者和21例接受了8个疗程该化疗的患者进行了比较。两组患者的二次剖腹探查率相似（10/16 vs. 14/21），二次剖腹探查阴性率也相似（6/10 vs. 9/14）。早期再次探查的优势可能在于毒性较低，且能更早识别出对初始化疗耐药的肿瘤患者。
